Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 convalescent plasma studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies -1% 13 14,426 Improvement, Studies, Patients Relative Risk, 95% CI Mortality -1% 13 14,426 Ventilation -1% 5 738 ICU admission 67% 1 160 Hospitalization 19% 3 580 Progression 11% 5 1,274 Recovery -1% 2 11,644 Viral clearance 41% 3 420 RCTs -1% 13 14,426 Peer-reviewed -0% 12 14,397 Early -93% 3 716 Late -0% 10 13,710 Convalescent Plasma for COVID-19 c19early.com/cp Dec 5, 2021 Favors conv. plasma Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 studies c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Effect extraction pre-specified Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 mortality results c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -163% 2.63 [0.43-9.10] 5/28 2/30 Tau​2 = 0.70; I​2 = 50.9% Early treatment -18% 1.18 [0.23-6.01] 7/108 6/110 -18% improvement Agarwal (RCT) 1% 0.99 [0.54-1.81] 19/227 19/224 Improvement, RR [CI] Treatment Control Bajpai (RCT) -221% 3.21 [0.38-27.4] 3/14 1/15 AlQahtani (RCT) 33% 0.67 [0.22-2.01] 4/20 6/20 Tau​2 = 0.00; I​2 = 0.0% Late treatment 3% 0.97 [0.58-1.63] 26/261 26/259 3% improvement All studies -1% 1.01 [0.63-1.62] 33/369 32/369 -1% improvement 5 convalescent plasma COVID-19 mechanical ventilation results c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.04 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 67% 0.33 [0.07-1.60] 2/80 6/80 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.07-1.60] 2/80 6/80 67% improvement All studies 67% 0.33 [0.07-1.59] 2/80 6/80 67% improvement 1 convalescent plasma COVID-19 ICU result c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.38 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 10% 0.90 [0.64-1.26] 51/257 56/254 10% improvement Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Improvement, RR [CI] Treatment Control AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Tau​2 = 0.00; I​2 = 0.0% Late treatment 23% 0.77 [0.61-0.96] 0/34 0/35 23% improvement All studies 19% 0.81 [0.67-0.97] 51/291 56/289 19% improvement 3 convalescent plasma COVID-19 hospitalization results c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.28 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 serious outcomes c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Effect extraction pre-specified Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Improvement, RR [CI] Treatment Control Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Tau​2 = 0.00; I​2 = 0.0% Late treatment -1% 1.01 [0.96-1.06] 1,963/5,838 1,941/5,806 -1% improvement All studies -1% 1.01 [0.96-1.06] 1,963/5,838 1,941/5,806 -1% improvement 2 convalescent plasma COVID-19 recovery results c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.35 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Improvement, RR [CI] Treatment Control Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) Tau​2 = 0.09; I​2 = 59.2% Late treatment 41% 0.59 [0.37-0.92] 60/213 91/207 41% improvement All studies 41% 0.59 [0.37-0.92] 60/213 91/207 41% improvement 3 convalescent plasma COVID-19 viral clearance results c19early.com/cp Dec 5, 2021 Tau​2 = 0.09; I​2 = 59.2%; Z = 2.31 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 Randomized Controlled Trials c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Effect extraction pre-specified Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 RCT mortality results c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.06] 1,639/7,075 1,563/6,606 -0% improvement All studies -0% 1.00 [0.93-1.08] 1,651/7,433 1,570/6,964 -0% improvement 12 convalescent plasma COVID-19 peer reviewed trials c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 1.3%; Z = 0.12 Effect extraction pre-specified Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Libster (DB RCT) 50% 0.50 [0.09-2.65] ventilation 2/80 4/80 Libster (DB RCT) 67% 0.33 [0.07-1.60] ICU 2/80 6/80 Libster (DB RCT) 48% 0.52 [0.29-0.94] progression 13/80 25/80 Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Balcells (RCT) -163% 2.63 [0.43-9.10] ventilation 5/28 2/30 Balcells (RCT) -23% 1.23 [0.56-1.89] progression 13/28 12/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Korley (RCT) 6% 0.94 [0.72-1.22] progression 77/257 81/254 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Li (RCT) 15% 0.85 [0.53-1.18] no improv. 25/52 29/51 Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Avendaño-Solà (RCT) 93% 0.07 [0.00-1.19] progression 0/38 7/43 Avendaño-Solà (RCT) 92% 0.08 [0.00-1.40] progression 0/38 6/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Agarwal (RCT) -7% 1.07 [0.73-1.58] progression 44/235 41/229 Agarwal (RCT) 1% 0.99 [0.54-1.81] ventilation 19/227 19/224 Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 Bajpai (RCT) -114% 2.14 [0.22-21.1] death 2/14 1/15 Bajpai (RCT) -221% 3.21 [0.38-27.4] ventilation 3/14 1/15 Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 AlQahtani (RCT) 33% 0.67 [0.22-2.01] ventilation 4/20 6/20 AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Simonovich (RCT) 19% 0.81 [0.50-1.31] 7-point status 228 (n) 105 (n) Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Bégin (RCT) -12% 1.12 [0.86-1.46] death 141/614 63/307 Bégin (RCT) -16% 1.16 [0.94-1.43] int./death 199/614 86/307 convalescent plasma COVID-19 outcomes c19early.com/cp Dec 5, 2021 Favors conv. plasma Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit